Galapagos « Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge!

3.327 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 163 164 165 166 167 » | Laatste

Omlaag ↓

tonneke 14 augustus 2015 09:15

quote:
aossa schreef op 14 augustus 2015 09:03:
Uit de krant:

Bijna nergens is Europa groeide het aantal miljonairs harder dan in Nederland: een groei van 16,5 procent in 2013, tot 173 duizend.

Wat doe ik dan verkeerd;-)))

aossa 14 augustus 2015 09:23

quote:
tonneke schreef op 14 augustus 2015 09:15:
[...]Wat doe ik dan verkeerd;-)))

Niets want het zijn cijfers uit 2013 :-))

[verwijderd] 14 augustus 2015 21:29

Curtis Carroll discovered the stock market in prison. Through friends and family on the outside, he invests from San Quentin State Prison in Northern California, and he's also an informal financial adviser to fellow inmates and correctional officers. Everyone in prison calls him Wall Street.

"I couldn't believe that this kind of access to this type of money could be accessible to anybody. Everybody should do it. And it's legal!" he says.

He pores over financial news: the Wall Street Journal, USA Today, Forbes. Business is like a soap opera, he says, and he's always trying to anticipate what will happen next. "I like to know what the CEO's doing," he says. "I like to know who's in trouble."

www.npr.org/2015/08/14/431958714/inma...

voda 17 augustus 2015 11:57

Esperite verkrijgt patent voor ontwikkeling immuuntherapieen

AMSTERDAM (Dow Jones)--Esperite nv (ESP.AE) heeft de volledige rechten gekregen voor het gebruik van een breed internationaal patent waarmee exosomen uit mesenchymale stamcellen (MSC) kunnen worden gebruikt in de ontwikkeling naar behandelingen tegen een breed aantal ontstekings- en auto-immuunziekten, zoals artritis, multiple sclerose, taaislijmziekte, type 1 diabetes, Graft- versus- host ziekte en hersen- en ruggenmergletsel.

Exosomen zijn kleine blaasjes die worden uitgescheiden door cellen en hebben bepaalde biologische markers die meer informatie kunnen geven over de prognose voor diverse ziektes, inclusief het opsporen van kanker. Ze helpen ook om medicijnen preciezer toe te dienen, waardoor de dosering kan worden verlaagd en bijwerkingen worden tegen gegaan.

De technologie waarvan Esperite nu het patent kan gebruiken, zorgt voor meer effectieve, veilige en betaalbare therapieen als een alternatief voor allogene stamceltherapieen, aldus het biotechbedrijf uit Zutphen.

Door Marleen Groen; Dow Jones Nieuwsdienst; +31 20 5715 200; marleen.groen@wsj.com

flosz 18 augustus 2015 16:19

De Galapagos-beleggers lopen de polonaise op het Galapagos-forum. Het aandeel noteert op een all time high en met +282,2% op het bord voor dit jaar is het bij uitstek het best presterende aandeel van het Damrak. En het feest is nog niet voorbij als het aan Jefferies ligt.
Vandaag gaat het aandeel opnieuw hard omhoog en dit keer door een rapport van Jefferies. We bedanken onze forumleden, want dankzij deze beleggers kunnen we het rapport inlezen. Een bloemlezing uit het rapport.
www.iex.nl/Column/162189/Jefferies-du...

voda 18 augustus 2015 16:22

Bedankt Flosz, had deze nog niet gelezen.

flosz 19 augustus 2015 12:47

AbbVie hands United a record $350M payoff for a speedy FDA review voucher
August 19, 2015 | By John Carroll

The cost of a priority review voucher for the FDA keeps going up. AbbVie is forking over a record $350 million to acquire a voucher from United Therapeutics, giving them an option at shaving 4 months off the agency's standard 10-month review process.

There's no immediate word from AbbVie ($ABBV) about which of their late-stage drugs will get the voucher, but at a cost of $87.5 million a month, the pharma company clearly has a potential blockbuster in mind. AbbVie and Roche are hustling the cancer drug venetoclax to the FDA for an accelerated review, with more late-stage therapies in the pipeline to pick from.

The FDA is using the vouchers to help encourage R&D for pediatric and tropical diseases, handing out the vouchers for new approvals in those two fields. And every new deal brings a new record price tag.

Sanofi and Regeneron drew considerable attention for their decision to pay the now bargain basement price of $67.5 million for a priority review voucher that allowed them to leapfrog Amgen on the first FDA approval for a PCSK9 cholesterol drug. Gilead scored a voucher for $125 million and then used it to accelerate a new HIV combo. And Sanofi fed the inflationary cycle with its $245 million voucher deal with Retrophin last May.

AbbVie has good reason to demonstrate a sense of urgency. The company is heavily dependent on Humira for most of its income and has to diversity its product portfolio as quickly as possible

In this case, United ($UTHR) gets to cash in on its approval of Unituxin, a new drug for rare cases of neuroblastoma.

"We are very pleased to monetize our PPRV, and hope that this transaction will encourage others to join us in focusing development efforts on rare pediatric diseases," said Roger Jeffs, United Therapeutics' president and co-CEO, in a statement.

twitter.com/johncfierce/status/633948...

aossa 20 augustus 2015 15:15

'Tsipras kondigt vanavond nog ontslag aan'

Het voortbestaan van de huidige Griekse regering hangt aan een zijden draadje. Volgens Griekse media zou premier Alexis Tsipras vanavond al zijn aftreden aankondigen. Nieuwe verkiezingen zouden dan voor 13 of 20 september kunnen zijn.

Het nieuws over het mogelijke ontslag van Tsipras lekte uit enkele uren nadat Griekenland van de eurolanden een eerste schijf van 13 miljard euro uit het nieuwe hulpprogramma ter waarde van 86 miljard euro had ontvangen. Daarmee kon het land meteen de Europese Centrale Bank (ECB) en het Internationaal Monetair Fonds (IMF) terugbetalen.

Maar net de voorwaarden die Griekenland moest slikken om dat geld te ontvangen, dreigen nu de huidige regering-Tsipras te doen vallen. De premier heeft het zwaar te verduren bij een deel van zijn partijgenoten.

etc.

Maycon 20 augustus 2015 16:38

Ben erg benieuwd wat er na de verkiezingen in Griekenland gaat gebeuren...

flosz 20 augustus 2015 17:45

NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS tinyurl.com/naupkx5 FIELD OF THE INVENTION
[0001] The present invention relates to the salt and crystalline forms of a compound according to Formula I, useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the salt of the invention inhibits JAK, a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the salt of the invention and methods for the prophylaxis and/or treatment of diseases including inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering a salt of the invention according to Formula I.

BACKGROUND OF THE INVENTION

[0002] Current therapies for treating inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, in particular rheumatoid arthritis, are far from satisfactory and there remains a need to identify new therapeutic agents that may be of use in their treatment. These conditions are chronic conditions which require long term therapy, and repeated intake of the drug. Long term treatment might be a heavy burden on the patient and the practitioner alike, since the patient might be or become intolerant to the drug, and furthermore high dosage, or high dosage frequency may result in uncomfortable side effects, and /or low patient compliance, where the patient may occasionally, deliberately or accidentally, miss a dose. The impact of non-adherence varies across chronic illnesses, and ranges from minimal to very significant (Ingersoll & Cohen, 2008). Therefore, there is a need to identify new agents to reinforce the arsenal of the practitioner, and compounds with low frequency dosage regimen to improve the life of the patients.

[0003] Janus kinases (JAKs) are cytoplasmic tyrosine kinases that transduce cytokine signaling from membrane receptors to STAT transcription factors. Four JAK family members are described, JAK1, JAK2, JAK3 and TYK2. Upon binding of the cytokine to its receptor, JAK family members auto- and/or transphosphorylate each other, followed by phosphorylation of STATs that then migrate to the nucleus to modulate transcription. JAK-STAT intracellular signal transduction serves the interferons, most interleukins, as well as a variety of cytokines and endocrine factors such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF and PRL (Vainchenker, Dusa, & Constantinescu, 2008).

[0004] The combination of genetic models and small molecule JAK inhibitor research revealed the therapeutic potential of several JAKs.

[0005] JAKl is a target in the immuno-inflammatory disease area. JAKl heterodimerizes with the other JAKs to transduce cytokine- driven pro-inflammatory signaling. Therefore, inhibition of JAKl is of interest for immuno-inflammatory diseases with pathology-associated cytokines that use JAKl signaling, such as IL-2, IL-6, IL-4, IL-5, IL-13, or IFNgamma, as well as for other diseases driven by JAK-mediated signal transduction.

[0006] In the JAK family members' roles, some overlap exists, since most signaling pathways involve more than one JAK, however for some growth factors such as erythropoietin and thrombopoietin, only JAK2 is involved.

[0007] JAK3 plays a major role in blocking immune function via transmission of signals generated by interleukin (IL)-2.

[0008] On the other hand, TYK2 would appear to work in combination with JAK2 in order to transduce signaling of cytokines such as IL-12 and IL-23.

[0009] The role of JAK enzymes has been mostly studied using mice where each of the JAK family members has been deleted. JAKl knockout mice exhibit a perinatal lethal phenotype and also have defective lymphoid development and function as a result of defective signaling by cytokines through JAKl . JAK2 deficiency results in embryonic lethality at day 12 as a result of a failure in definitive erythropoiesis. JAK3- deficient mice have severe combined immunodeficiency (SCID) phenotype but do not have non-immune defects (Verstovsek, 2009).

[0010] As has been observed with pan JAK inhibitors, non-selective inhibition may be linked to side effects such as anemia , an increased rate of infections, lower neutrophil and lymphocyte counts, a decrease in haemoglobin, and elevated cholesterol levels (Dolgin, 2011).

[0011] Therefore, the development of a selective JAK inhibitor would be beneficial in order to minimize such side effects.

[0012] The degeneration of cartilage is the hallmark of various diseases, among which rheumatoid arthritis and osteoarthritis are the most prominent. Rheumatoid arthritis (RA) is a chronic joint degenerative disease, characterized by inflammation and destruction of the joint structures. When the disease is untreated, it can lead to substantial disability and pain due to loss of joint function and result in shortened life-expectancy. The aim of a RA therapy, therefore, is not only to slow down the disease but to attain remission in order to stop the joint destruction and improve quality of life. Besides the severity of the disease outcome, the high prevalence of RA (~ 0.8% of adults are affected worldwide) means a high socio-economic impact. (Smolen & Steiner, 2003) (O'Dell, 2004). JAKl is implicated in intracellular signal transduction for many cytokines and hormones. Pathologies associated with any of these cytokines and hormones can be ameliorated by JAKl inhibitors. Hence, several allergy, inflammation and autoimmune disorders might benefit from treatment with compounds described in this invention including rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), tissue fibrosis, eosinophilic inflammation, eosophagitis, inflammatory bowel diseases (e.g. Crohn's disease, ulcerative colitis), transplant, graft-versus-host

disease, psoriasis, myositis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and multiple sclerosis. (Kopf, Bachmann, & Marsland, 2010)

[0013] Psoriasis is a disease that can affect the skin. The cause of psoriasis is not fully understood but it is believed that it is an immune mediated related disease linked to the release of cytokines, in particular TNFa, which causes inflammation and rapid reproduction of the skin cells. This hypothesis has been corroborated by the observation that immunosuppressant medication can clear psoriasis plaques. (Zenz, et al., 2005) Psoriasis can also cause inflammation of the joints, which is known as psoriatic arthritis. Between 10-30% of all people with psoriasis also have psoriatic arthritis. ((CHMP), 18 November 2004) Because of its chronic recurrent nature, psoriasis is a challenge to treat. It has recently been demonstrated that inhibition of JAK could result in successful improvement of the psoriatic condition (Punwani, et al., 2012).
Meer via link.

flosz 20 augustus 2015 17:46

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS tinyurl.com/pbumqbk

Bijlage:

Maycon 20 augustus 2015 17:48

quote:
flosz schreef op 20 augustus 2015 17:46:
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS tinyurl.com/pbumqbk

Geweldige bijdrage flosz thx....(AB)

flosz 20 augustus 2015 17:57

quote:
flosz schreef op 11 augustus 2015 20:19:
[Modbreak IEX: Gelieve op uw taalgebruik te letten, bericht is bij dezen verwijderd.]

Beste mod., TERING is een ander woord voor TBC.
Hier geplaatst met een link richting jaarverslag AERAS, die verzetten namelijk gigantisch veel werk om een oplossing te zoeken tegen TBC, TERING dus.............
Probeer eens wat te lezen(ook @langetenenmetbordvoordekop): Annual Report 2014
www.aeras.org/annualreport2014/

Bijlage:

[verwijderd] 20 augustus 2015 17:58

The FDA Is Basically Approving Everything. Here's The Data To Prove It

Matthew Herper
FORBES STAFF

Remember when the FDA rejected drugs?

We just got treated to a whole lot of drama this week as to whether Addyi, a drug to boost women’s libidos, would be approved. But based on the data, that approval was probably a foregone conclusion.

As recently as 2008, companies filing applications to sell never-before-marketed drugs, which are referred to by the FDA as “new molecular entities,” faced rejection 66% of the time. Yet so far this year the FDA has rejected only three uses for new chemical entities, and approved 25, an approval rate of 89%.

Those numbers come from a new analysis commissioned by Forbes from BioMedTracker, a division of publishing giant Informa that helps investors track events in the pharmaceutical industry. And if you dig into them, the drop is even sharper.

www.forbes.com/sites/matthewherper/20...

aossa 20 augustus 2015 18:10

quote:
flosz schreef op 20 augustus 2015 17:57:
[...]
Beste mod., TERING is een ander woord voor TBC.

Klopt op de lagere school leerden we over TERING en over de PEST...
Er was een jongen die zei dat zijn vader een TERINGLIJDER was en voor enkele maanden naar het sanatorium was om de herstellen.

[verwijderd] 20 augustus 2015 18:57

@Chicken little

Thanxs mate voor dat FDA artikel.
Blijkt dat een van mijn holdings binnen 3 weken hoort of de BLA wordt geaccepteerd voor review. Gebaseerd op jou artikel .......
Overigens is de rubber stamp verwachting nog niet echt in de koers opgenomen, maar ja wat in het vat zit.

[verwijderd] 20 augustus 2015 19:15

quote:
aossa schreef op 20 augustus 2015 18:10:
[...]
Klopt op de lagere school leerden we over TERING en over de PEST...
Er was een jongen die zei dat zijn vader een TERINGLIJDER was en voor enkele maanden naar het sanatorium was om de herstellen.

Anderzijds ligt posten over je schooltijd vandaag erg gevoelig voor sommige leden.
Mogelijke oorzaak : Voda is met vakantie

aossa 20 augustus 2015 23:52

Bedrijf van vrouwelijke Viagra al na 1 dag overgenomen

Soms gaat het wel heel erg snel. Gisteren kondigde Sprout Pharmaceuticals aan dat het van de FDA zijn lustpil voor vrouwen - merknaam: Addyi - op de Amerikaanse markt mag brengen. nog geen 24 uur later volgde het bericht dat Valeant het bedrijf overneemt.

Valeant VRX -6,47% betaalt 1 miljard dollar cash, en zal een extraatje betalen als de 'vrouwelijke Viagra' bepaalde verkoopdrempels haalt.

Voor Valeant tikt het rijtje overnames verder aan. Het miljardenbedrijf ontpopte zich tot dé deal maker in de farmasector.

www.nasdaq.com/symbol/vrx

flosz 22 augustus 2015 10:37

AbbVie Inc May Use Priority Voucher To Gain Lymphoma Lead Over Roche Holding Ltd.
AbbVie paid $350 million to buy a priority review voucher yesterday. Here’s what analysts believe the voucher can be used for.

On Wednesday, AbbVie Inc. (NYSE:ABBV) purchased a rare pediatric priority review voucher from United Therapeutics Corporation (NASDAQ:UTHR) for $350 million. United had received the voucher in March after the Food and Drug Administration (FDA) approved its drug, Unituxin, for the treatment of neuroblastoma. The voucher program aims at boosting development of neglected disease drugs.

The voucher will help AbbVie to expedite the review process for one of its drugs, from a standard 10 months to 6 months. The company has not yet disclosed its plans for the voucher’s use, giving rise to speculations. Bloomberg Intelligence analysts Elizabeth Krutoholow and Grace Guo believe the company will use the voucher to file its blockbuster cancer drug Imbruvica, for expanded indication in relapsed or refractory follicular lymphoma.

www.bidnessetc.com/50631-abbvie-inc-m...

Bijlage:

aston.martin 23 augustus 2015 10:06

quote:
flosz schreef op 20 augustus 2015 17:46:
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS tinyurl.com/pbumqbk

Wie is er thuis in deze materie?
AbbVie heeft nog geen licentie maar vraagt een patent aan om filgotinib te gebruiken. Wat zijn dan op dat ogenblik de wettelijke consequenties omtrent het gebruik van figotinib?

3.327 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 ... 163 164 165 166 167 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	25 apr 2024 17:35
Koers	26,560
Verschil	0,000 (0,00%)
Hoog	26,980
Laag	26,380
Volume	112.312
Volume gemiddeld	81.657
Volume gisteren	112.312

Galapagos nieuws meer

12 apr	KBC Securities verlaagt koersdoel Gal...
05 apr	Galapagos toont innovatieve aanpak in...
23 feb	AEX op de waakvlam het weekend in, ko...	2
23 feb	Beursblik: gebrek aan opwaarts potent...
23 feb	Gaat AEX op recordjacht of gaat de be...
23 feb	Update : Galapagos voldoet aan verwac...
19 feb	Beursblik: cashburn belangrijk voor G...
15 feb	Galapagos presenteert nieuwe onderzoe...
01 feb	Galapagos rondt Jyseleca-transactie af
04 jan	Galapagos in zee met Thermo Fisher